HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dropped-head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS-mutated metastatic melanoma.

AuthorsJ Kleemann, I Hrgovic, K Hempel, R Kaufmann, M Meissner
JournalClinical and experimental dermatology (Clin Exp Dermatol) Vol. 43 Issue 2 Pg. 195-196 (03 2018) ISSN: 1365-2230 [Electronic] England
PMID29023842 (Publication Type: Case Reports, Letter)
Chemical References
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • Mitogen-Activated Protein Kinase Kinases
Topics
  • Head
  • Humans
  • Male
  • Melanoma (drug therapy, secondary)
  • Middle Aged
  • Mitogen-Activated Protein Kinase Kinases (antagonists & inhibitors)
  • Muscle Weakness (chemically induced)
  • Neck Muscles (drug effects)
  • Protein Kinase Inhibitors (adverse effects)
  • Pyridones (adverse effects)
  • Pyrimidinones (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: